CriticalDirect oral anticoagulants (factor Xa inhibitors)×Direct oral anticoagulants (factor Xa inhibitors)
Updated · Methodology
Mechanism
Edoxaban and rivaroxaban both directly inhibit the same clotting factor, factor Xa, and reduce thrombin generation (edoxaban and rivaroxaban summaries of product characteristics, SmPCs, European Medicines Agency, EMA). Both SmPCs contraindicate use with any other anticoagulant because of the increased risk of bleeding, and the edoxaban SmPC names rivaroxaban (EMA). Healthy volunteers took rivaroxaban for three days and switched to edoxaban on day 4. After the switch, their prothrombin time was the same as on day 3 of rivaroxaban (edoxaban SmPC, EMA). This is why the first edoxaban dose after a switch can be given at the time of the next scheduled dose of the previous drug (EMA).
Symptoms
Edoxaban increases the risk of bleeding, which can be severe or even fatal and can occur at any site (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Bleeding can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). If haemoglobin or blood pressure falls without explanation, look for a bleeding site. Standard coagulation tests are not suitable for monitoring the effect of edoxaban (EMA).
Management
Edoxaban is contraindicated with any other anticoagulant, except when switching from one oral anticoagulant to another. The edoxaban summary of product characteristics (SmPC) names rivaroxaban in this contraindication (edoxaban SmPC, European Medicines Agency, EMA). The rivaroxaban SmPC likewise contraindicates any other anticoagulant except in specific circumstances, including a switch of anticoagulant therapy (rivaroxaban SmPC, EMA). When switching from rivaroxaban to edoxaban, stop rivaroxaban and start edoxaban at the time of the next scheduled rivaroxaban dose (edoxaban SmPC, EMA). When switching from edoxaban to rivaroxaban, stop edoxaban and start rivaroxaban at the time of the next scheduled edoxaban dose (EMA). The US edoxaban label does not recommend long-term use of edoxaban with other anticoagulants (edoxaban label, US Food and Drug Administration, FDA). The US rivaroxaban label says to avoid other anticoagulants with rivaroxaban unless the benefit outweighs the risk (rivaroxaban label, FDA). Promptly evaluate any signs of blood loss (edoxaban label, FDA). If severe bleeding occurs, stop edoxaban. There is no specific antidote (EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Xarelto (rivaroxaban) prescribing information (2026)– FDA label, DailyMed setid 10db92f9-2300-4a80-836b-673e1ae91610, version 65, revised 09/2026, sections 5.2 and 7
- EMA: Ficha técnica: Rivaroxabán (EU/1/08/472), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, nº 08472018 (EU/1/08/472), sección 4.3, consultado 10/2026
- FDA: SAVAYSA (edoxaban) tablets, prescribing information (2023)– FDA, SAVAYSA (edoxaban tosylate) prescribing information, Daiichi Sankyo, NDA 206316, revised 10/2023 (DailyMed)
- EMA: Ficha técnica: Edoxabán, Lixiana 60 mg (EU/1/15/993), sección 4.3 (2025)– EMA SmPC vía AEMPS CIMA, Lixiana 60 mg comprimidos recubiertos con película (Daiichi Sankyo Europe), nº registro 115993018 (EU/1/15/993), información de producto EMA actualizada 27/08/2025, consultada 30.10.2026, secciones 4.2, 4.3, 4.4, 4.5, 4.8, 4.9 y 5.1